Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

NCT02417103 on ClinicalTrials.gov · last registry update 2022-06-30

Stopped early, having planned 2 participants. The sponsor logged completion for September 2016. Primary outcome, as filed: weight reduction. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor type: Other
Enrollment: 2
Started: 2011-12
Primary completion: 2016-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

weight reduction

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.